R&D Archives -

Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-up

https://pharmaphorum.com/news/neurocrine-and-xenon-agree-1-75bn-epilepsy-rd-tie-up/

FDA tags psilocybin drug as clinical depression Breakthrough Therapy

https://pharmaphorum.com/news/fda-tags-psilocybin-drug-as-clinical-depression-breakthrough-therapy/

ViGeneron to develop next-gen eye gene therapies after funding round

https://pharmaphorum.com/news/vigeneron-to-develop-next-gen-eye-gene-therapies/

Could AI create a brave new world of pharma R&D?

https://deep-dive.pharmaphorum.com/magazine/digital-health/ai-pharma-rd/

Conservatives shy away from drug price debate in election manifesto

https://pharmaphorum.com/news/conservatives-shy-away-from-drug-price-debate-in-election-manifesto/

AbbVie signs potential $2.4bn cancer immunotherapy deal with Harpoon

https://pharmaphorum.com/news/abbvie-signs-potential-2-4bn/

Biofabri’s TB vaccine collaboration presses ahead with vaccine trial

https://pharmaphorum.com/news/biofabris-tb-vaccine-collaboration-presses-ahead-with-vaccine-trial/

6 Ways To Finally Drug RAS Oncogenes

https://pharmaphorum.com/partner-content/6-ways-to-finally-drug-ras-oncogenes/

UK should pay $25 million for ‘Netflix’ antibiotic subscription

https://pharmaphorum.com/news/uk-should-pay-at-least-25-million-for-netflix-antibiotic-subscription-says-expert/

Search